Continuous AI medical device monitoring will become a central part of Britain’s healthcare technology framework after the UK government accepted all 44 recommendations from its national commission on AI regulation. The policy shifts oversight away from relying mainly on approval before deployment and toward evidence gathered throughout a product’s working life.

 

The government response commits the MHRA to four major changes:

  • Stronger surveillance after AI devices enter clinical use.
  • Controls for model updates through predetermined change plans.
  • Improved incident reporting and a public safety database.
  • New guidance, pilots and possible legislative reforms by spring 2027.

 

Continuous AI Medical Device Monitoring Replaces One-Time Assurance

The formal government response, published on October 6, accepts a lifecycle-based approach for software and AI-enabled medical devices. Regulators would collect evidence after deployment, monitor changing performance and respond to safety signals rather than treating market approval as the end of scrutiny.

 

The distinction matters because an adaptive system can behave differently as its software, data or clinical environment changes. Performance measured before launch may not reveal how a model will work across new hospitals, patient populations, equipment or workflows months later.

 

The Medicines and Healthcare products Regulatory Agency will develop enhanced post-market surveillance mechanisms and clearer evidence expectations. It will also examine licensing powers, secondary legislation and guidance needed to make ongoing oversight enforceable and proportionate to each device’s risk.

 

This is a policy commitment rather than a complete rulebook already in force. The cross-system implementation plan and roadmap are due by spring 2027, with annual progress reports planned after publication.

 

AI Airlock Phase Three Will Test Post-Market Surveillance

The MHRA will use the third phase of its AI Airlock regulatory sandbox to investigate how post-market surveillance can work in practice. The programme lets regulators, developers and healthcare organisations examine difficult compliance questions before final rules are applied across the market.

 

Phase three will focus on lifecycle monitoring after devices enter clinical use. Applications are set to open as the regulator tests mechanisms that could be required individually or together, depending on a product’s risk, functionality and pattern of change.

 

Predetermined Change Control Plans are another key element. A manufacturer would define the boundaries within which an AI system may be modified without restarting the complete approval process, while documenting how safety and performance will remain controlled as the model evolves.

 

The MHRA intends to issue draft guidance on those plans for public comment by December 2026. The proposed approach would cover adaptive AI devices and describe allowable categories of change rather than requiring every future modification to be specified in advance.

 

Incident Reports and Device Versions Will Become Easier to Trace

The government accepted recommendations to strengthen reporting between manufacturers, regulators, healthcare providers, professionals and patients. Monitoring requirements could be incorporated into change-control plans, while hospitals and product users may gain simpler ways to submit feedback during routine use.

 

The existing Yellow Card safety scheme is expected to receive software-specific reporting improvements. The response also proposes exploring automated, low-burden reports embedded in electronic patient records or AI products, reducing dependence on clinicians manually completing a separate process.

 

A planned public database would allow patients and clinicians to search adverse-incident reports involving medical devices, including AI-enabled software. The MHRA will also consider a regularly updated list of authorised AI devices, giving the public a clearer view of products permitted in the UK.

 

Traceability will extend to software versions. Guidance on mandatory unique device identifiers is expected to include AI systems and version control across updates, with relevant information captured in electronic patient records so an incident can be connected to the precise model release involved.

 

The UK Plan Balances Earlier Access With Stronger Enforcement

The framework is not designed only to add controls. It also supports staged authorisations, regulatory sandboxes and international recognition pathways intended to give patients earlier access to promising technology while developers generate real-world evidence under tighter supervision.

 

Britain’s medicines regulator told Reuters that AI medical devices require continuing scrutiny because some algorithms can evolve while clinicians use them. The government will publish delivery targets and timelines in the implementation plan rather than assuming every recommendation can take effect immediately.

 

The response also opens the door to stronger enforcement. The MHRA will examine civil financial penalties under the Medicines and Medical Devices Act and additional mechanisms for communicating emerging safety or quality signals across the health system.

 

Manufacturers therefore face a more demanding but potentially clearer route to market. A device may receive supervised early access, yet its developer would remain responsible for monitoring real-world performance, controlling updates, reporting failures and supplying evidence throughout the lifecycle.

 

The decisive details remain unfinished. Guidance must define which products qualify as medical devices, how risk categories apply, what evidence manufacturers must collect and when a performance change triggers regulatory action. Until that work is published, the October response establishes direction and accountability, not a fully operational regime.

 

Further Reading